ID   MIEN1_HUMAN             Reviewed;         115 AA.
AC   Q9BRT3;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   28-JUN-2023, entry version 154.
DE   RecName: Full=Migration and invasion enhancer 1;
DE   AltName: Full=HBV X-transactivated gene 4 protein;
DE   AltName: Full=HBV XAg-transactivated protein 4;
DE   AltName: Full=Protein C35;
DE   Flags: Precursor;
GN   Name=MIEN1; Synonyms=C17orf37, RDX12, XTP4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND
RP   ISOPRENYLATION.
RX   PubMed=17121940; DOI=10.1158/1535-7163.mct-06-0389;
RA   Evans E.E., Henn A.D., Jonason A., Paris M.J., Schiffhauer L.M.,
RA   Borrello M.A., Smith E.S., Sahasrabudhe D.M., Zauderer M.;
RT   "C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast
RT   cancer.";
RL   Mol. Cancer Ther. 5:2919-2930(2006).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Liu Y., Cheng J., Lu Y., Wang G., Zhang L., Chen J., Li L.;
RT   "Cloning and identification of human gene 4 transactivated by hepatitis B
RT   virus X antigen.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND ISOPRENYLATION AT
RP   CYS-112.
RX   PubMed=19503095; DOI=10.1038/onc.2009.145;
RA   Dasgupta S., Wasson L.M., Rauniyar N., Prokai L., Borejdo J.,
RA   Vishwanatha J.K.;
RT   "Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of
RT   prostate cancer cells.";
RL   Oncogene 28:2860-2872(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, ISOPRENYLATION AT CYS-112, AND MUTAGENESIS
RP   OF CYS-112 AND 112-CYS--LEU-115.
RX   PubMed=21628459; DOI=10.1074/jbc.m111.254599;
RA   Dasgupta S., Cushman I., Kpetemey M., Casey P.J., Vishwanatha J.K.;
RT   "Prenylated c17orf37 induces filopodia formation to promote cell migration
RT   and metastasis.";
RL   J. Biol. Chem. 286:25935-25946(2011).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [10]
RP   STRUCTURE BY NMR, AND DISULFIDE BOND.
RX   PubMed=23284973; DOI=10.1371/journal.pone.0052292;
RA   Hsu C.H., Shen T.L., Chang C.F., Chang Y.Y., Huang L.Y.;
RT   "Solution structure of the oncogenic MIEN1 protein reveals a thioredoxin-
RT   like fold with a redox-active motif.";
RL   PLoS ONE 7:E52292-E52292(2012).
CC   -!- FUNCTION: Increases cell migration by inducing filopodia formation at
CC       the leading edge of migrating cells. Plays a role in regulation of
CC       apoptosis, possibly through control of CASP3. May be involved in a
CC       redox-related process. {ECO:0000269|PubMed:19503095,
CC       ECO:0000269|PubMed:21628459}.
CC   -!- SUBUNIT: Interacts with GPX1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q9BRT3; Q03989: ARID5A; NbExp=3; IntAct=EBI-6137472, EBI-948603;
CC       Q9BRT3; Q96D03: DDIT4L; NbExp=3; IntAct=EBI-6137472, EBI-742054;
CC       Q9BRT3; Q9H8Y8: GORASP2; NbExp=3; IntAct=EBI-6137472, EBI-739467;
CC       Q9BRT3; Q8WUI4-6: HDAC7; NbExp=5; IntAct=EBI-6137472, EBI-12094670;
CC       Q9BRT3; Q14774: HLX; NbExp=3; IntAct=EBI-6137472, EBI-6678255;
CC       Q9BRT3; P26583: HMGB2; NbExp=6; IntAct=EBI-6137472, EBI-1057009;
CC       Q9BRT3; P78424: POU6F2; NbExp=3; IntAct=EBI-6137472, EBI-12029004;
CC       Q9BRT3; Q04864: REL; NbExp=3; IntAct=EBI-6137472, EBI-307352;
CC       Q9BRT3; Q04864-2: REL; NbExp=3; IntAct=EBI-6137472, EBI-10829018;
CC       Q9BRT3; Q15654: TRIP6; NbExp=3; IntAct=EBI-6137472, EBI-742327;
CC       Q9BRT3; O95231: VENTX; NbExp=3; IntAct=EBI-6137472, EBI-10191303;
CC       Q9BRT3; A0A0C4DGF1: ZBTB32; NbExp=5; IntAct=EBI-6137472, EBI-10188476;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane; Lipid-anchor;
CC       Cytoplasmic side. Note=Concentrates at the leading edge of migrating
CC       cells. Localizes outside membrane raft regions.
CC   -!- TISSUE SPECIFICITY: Among normal tissues, present only in Leydig cells.
CC       Strongly up-regulated in breast cancers and in brain cancer distant
CC       metastasis (at protein level). Up-regulated in prostate cancer cells
CC       and in the higher grades of prostate adenocarcinoma (at protein level).
CC       {ECO:0000269|PubMed:17121940, ECO:0000269|PubMed:19503095}.
CC   -!- PTM: Isoprenylation facilitates association with the plasma membrane
CC       and enhances the migratory phenotype of cells by inducing increased
CC       filopodia formation. {ECO:0000269|PubMed:17121940,
CC       ECO:0000269|PubMed:19503095, ECO:0000269|PubMed:21628459}.
CC   -!- SIMILARITY: Belongs to the SelWTH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/52476/MIEN1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY508814; AAR92035.1; -; mRNA.
DR   EMBL; AF490253; AAO85461.1; -; mRNA.
DR   EMBL; AC079199; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006006; AAH06006.1; -; mRNA.
DR   CCDS; CCDS11344.1; -.
DR   RefSeq; NP_001317135.1; NM_001330206.1.
DR   RefSeq; NP_115715.3; NM_032339.4.
DR   PDB; 2LJK; NMR; -; A=1-115.
DR   PDBsum; 2LJK; -.
DR   AlphaFoldDB; Q9BRT3; -.
DR   BMRB; Q9BRT3; -.
DR   SMR; Q9BRT3; -.
DR   BioGRID; 124025; 19.
DR   IntAct; Q9BRT3; 13.
DR   STRING; 9606.ENSP00000377778; -.
DR   iPTMnet; Q9BRT3; -.
DR   PhosphoSitePlus; Q9BRT3; -.
DR   BioMuta; MIEN1; -.
DR   DMDM; 74732925; -.
DR   EPD; Q9BRT3; -.
DR   jPOST; Q9BRT3; -.
DR   MassIVE; Q9BRT3; -.
DR   MaxQB; Q9BRT3; -.
DR   PaxDb; Q9BRT3; -.
DR   PeptideAtlas; Q9BRT3; -.
DR   ProteomicsDB; 78828; -.
DR   Antibodypedia; 28368; 604 antibodies from 26 providers.
DR   DNASU; 84299; -.
DR   Ensembl; ENST00000394231.8; ENSP00000377778.3; ENSG00000141741.12.
DR   GeneID; 84299; -.
DR   KEGG; hsa:84299; -.
DR   MANE-Select; ENST00000394231.8; ENSP00000377778.3; NM_032339.5; NP_115715.3.
DR   UCSC; uc002hsq.4; human.
DR   AGR; HGNC:28230; -.
DR   CTD; 84299; -.
DR   DisGeNET; 84299; -.
DR   GeneCards; MIEN1; -.
DR   HGNC; HGNC:28230; MIEN1.
DR   HPA; ENSG00000141741; Low tissue specificity.
DR   MIM; 611802; gene.
DR   neXtProt; NX_Q9BRT3; -.
DR   OpenTargets; ENSG00000141741; -.
DR   PharmGKB; PA134947080; -.
DR   VEuPathDB; HostDB:ENSG00000141741; -.
DR   eggNOG; ENOG502S3GR; Eukaryota.
DR   GeneTree; ENSGT00390000010440; -.
DR   HOGENOM; CLU_068510_4_0_1; -.
DR   InParanoid; Q9BRT3; -.
DR   OMA; AAPIKDC; -.
DR   OrthoDB; 5471482at2759; -.
DR   PhylomeDB; Q9BRT3; -.
DR   TreeFam; TF326627; -.
DR   PathwayCommons; Q9BRT3; -.
DR   SignaLink; Q9BRT3; -.
DR   BioGRID-ORCS; 84299; 45 hits in 1151 CRISPR screens.
DR   ChiTaRS; MIEN1; human.
DR   GenomeRNAi; 84299; -.
DR   Pharos; Q9BRT3; Tbio.
DR   PRO; PR:Q9BRT3; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9BRT3; protein.
DR   Bgee; ENSG00000141741; Expressed in mucosa of transverse colon and 182 other tissues.
DR   ExpressionAtlas; Q9BRT3; baseline and differential.
DR   Genevisible; Q9BRT3; HS.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IDA:UniProtKB.
DR   Gene3D; 3.40.30.10; Glutaredoxin; 1.
DR   InterPro; IPR011893; Selenoprotein_Rdx-typ.
DR   InterPro; IPR036249; Thioredoxin-like_sf.
DR   PANTHER; PTHR15124:SF15; MIGRATION AND INVASION ENHANCER 1; 1.
DR   PANTHER; PTHR15124; SELENOPROTEIN W; 1.
DR   Pfam; PF10262; Rdx; 1.
DR   SUPFAM; SSF52833; Thioredoxin-like; 1.
DR   TIGRFAMs; TIGR02174; CXXU_selWTH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; Cell membrane; Cytoplasm;
KW   Disulfide bond; Lipoprotein; Membrane; Prenylation; Redox-active center;
KW   Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..112
FT                   /note="Migration and invasion enhancer 1"
FT                   /id="PRO_0000265099"
FT   PROPEP          113..115
FT                   /note="Removed in mature form"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000396008"
FT   REGION          1..21
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   LIPID           112
FT                   /note="S-geranylgeranyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:19503095,
FT                   ECO:0000269|PubMed:21628459"
FT   DISULFID        30..33
FT                   /note="Redox-active"
FT                   /evidence="ECO:0000269|PubMed:23284973"
FT   MUTAGEN         112..115
FT                   /note="Missing: No effect on subcellular location. Low
FT                   protein abundance, suggesting that stability is affected."
FT                   /evidence="ECO:0000269|PubMed:21628459"
FT   MUTAGEN         112
FT                   /note="C->S: Abolishes prenylation. Predominantly cysolic
FT                   with little plasma membrane-associated expression. Reduces
FT                   cell migration by affecting filopodia formation."
FT                   /evidence="ECO:0000269|PubMed:21628459"
FT   STRAND          26..29
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   TURN            31..34
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   HELIX           36..46
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   STRAND          51..53
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   STRAND          56..59
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   STRAND          61..63
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   STRAND          65..68
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   HELIX           77..80
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   TURN            86..90
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   HELIX           91..96
FT                   /evidence="ECO:0007829|PDB:2LJK"
FT   TURN            97..99
FT                   /evidence="ECO:0007829|PDB:2LJK"
SQ   SEQUENCE   115 AA;  12403 MW;  5D8B911C0F23DDC1 CRC64;
     MSGEPGQTSV APPPEEVEPG SGVRIVVEYC EPCGFEATYL ELASAVKEQY PGIEIESRLG
     GTGAFEIEIN GQLVFSKLEN GGFPYEKDLI EAIRRASNGE TLEKITNSRP PCVIL
//
